Wednesday, January 12, 2011

510(k) Reform: Adapting to New FDA Standards and Changes

Share | Facebook Twitter LinkedIn Email a Colleague

 

The FDA is preparing to announce planned 510(k) program reforms by the end of December 2010, as stated by CDRH Director Jeffrey Shuren on December 1. But major concerns remain: Will devices get cleared and approved at a faster pace? Will the FDA give the device industry what it wants – predictability, transparency and reasonable data requirements?


During this webinar, Mark DuVal, one of the leading attorneys and advocates for medical device makers, will discuss the current status of the 510(k) reform, new changes to the program, increasing Congressional commentary and what device makers need to prepare for in the months ahead.

 

In 90 minutes, you will discover:

  • Industry is in “tweener” status: FDA’s internal Working Group and IOM recommendations are proposed, but not finalized
  • FDA has brought on intense and increasingly loud Congressional commentary and oversight—who is speaking out?
  • Is FDA listening, and where are we headed?
  • How have the elections changed the complexion of things?
  • What does this mean for the review of current 510(k) submissions?

Mark will also answer your team's questions in the Q&A session.


For one low price, you and your entire team from one location can take part in this fast-paced, insightful webinar. Best of all, you'll be able to connect personally with our panelists when we open up the phone lines for live Q&A.

Speaker

Mark DuVal

Mark DuVal President

DuVal & Associates, P.A.

Mark DuVal is President of DuVal & Associates, P.A., where his practice includes providing strategic regulatory advice, developing compliance programs, designing and implementing sophisticated marketing programs, counseling on reimbursement matters, conducting sales training and interfacing extensively on behalf of companies with the FDA, clinical trial negotiations and more.

Prior to founding the firm, Mark was general counsel for 3M Pharmaceuticals and Drug Delivery Systems working both domestically and internationally. He was on assignment for 3M Health Care Systems, Ltd. In Europe based out of the United Kingdom. He then worked at Medtronic in Corporate Compliance for FDA, Anti-kickback, False Claims Act, HIPAA & HITECH, and other advice related to the FDA-regulated industry. Mark earned his J.D. with honors from the William Mitchell College of Law. He is a frequent speaker and author of articles and papers addressing FDA topics.

Registration

Transcript & Audio

Audio CD & Transcript
$349


Purchase

24/7 ENCORE Audio Presentation

24/7 ENCORE Audio Presentation
$349


Purchase

Cancellations: No refunds will be given for webinar or virtual conference cancellations. To request a credit memo, please contact EBI Customer Care via email at custcare@elsevier.com. Registrants may substitute the 24/7 ENCORE Audio Presentation or the Audio CD & Transcript package for the Live Webinar at any time.